Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration had said on Monday it has approved generic versions of Vyvanse from 11 drugmakers after Takeda's exclusivity over the drug expired on Aug. 24.
(Reuters) -The U.S. Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing ...
The Drug Enforcement Administration is increasing the production limit of Vyvanse and its generic equivalents by about 24% to address the ongoing global shortage of ADHD medications.
Lisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. [16] Lisdexamfetamine is taken by mouth. Its effects generally begin within two hours ...
Drug Main indication Trade name 2015 2016 ... Vyvanse: Lisdexamfetamine: 447,188: ... Takeda Pharmaceuticals North America, Inc:
In 2014 Shire acquired two rare disease drug companies: Fibrotech [21] with its antifibrotic compounds for $75 million, and Lumena, a company researching rare gastro-intestinal and hepatic compounds, for $260 million. [22] In 2015, NPS Pharmaceuticals was acquired for $5.2 billion, bringing along its rare disease drugs Gattex and Natpara. [23]
Takeda Pharmaceuticals, which makes Vyvanse, also known as lisdexamfetamine, its generic, says there’s no shortage of that drug, but according to dozens of pharmacies reached by NBC News ...
Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo; Viibryd – an antidepressant of the serotonin modulator and stimulators class; Vivactil (protriptyline) an antidepressant also used in the treatment of nerve pain